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Cyclin-dependent kinases (CDKs) drive cell cycle 
progression and control transcriptional pro-
cesses. The dysregulation of multiple CDK family 
members occurs commonly in human cancer; in 
particular, the cyclin D-CDK4/6-retinoblastoma 
protein (RB)-iNK4 axis is universally disrupted, 
facilitating cancer cell proliferation and prompt-
ing long-standing interest in targeting CDK4/6 
as an anticancer strategy. Most agents that 
have been tested inhibit multiple cell cycle and 
transcriptional CDKs and have carried toxicity. 
However, several selective and potent inhibitors 
of CDK4/6 have recently entered clinical trial. 
PD0332991, the first to be developed, resulted 
from the introduction of a 2-aminopyridyl sub-
stituent at the C2-position of a pyrido(2,3-d)
pyrimidin-7-one backbone, affording exqui-
site selectivity toward CDK4/6.1 PD0332991 
arrests cells in G1 phase by blocking RB phos-
phorylation at CDK4/6-specfic sites and does 
not inhibit the growth of RB-deficient cells.2 
Phase i studies conducted in patients with 
advanced RB-expressing cancers demonstrated 
mild side effects and dose-limiting toxicities 
of neutropenia and thrombocytopenia, with 
prolonged stable disease in 25% of patients.3,4 
in cyclin D1-translocated mantle cell lymphoma, 
PD0332991 extinguished CDK4/6 activity in 
patients’ tumors, resulting in markedly reduced 
proliferation, and translating to more than 1 
year of stability or response in 5 of 17 cases.5
Two recent papers from the Knudsen 
laboratory make several important obser-
vations that will help guide the continued 
clinical development of CDK4/6 inhibitors. in 
the study by Dean et al., surgically resected 
patient breast tumors were grown on a tissue 
culture matrix in the presence or absence of 
PD0332991. Crucially, these cultures retained 
associated stromal components known to 
play important roles in cancer pathogenesis 
and therapeutic sensitivities, as well as key 
histological and molecular features of the pri-
mary tumor, including expression of eR, HeR2 
and Ki-67. Similar to results in breast cancer 
cell lines,6 the authors demonstrate that only 
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RB-positive tumors have growth inhibition in 
response to PD0332991, irrespective of eR or 
HeR2 status, while tumors lacking RB were 
completely resistant. This result underscores 
RB as the predominant target of CDK4/6 in 
breast cancer cells and the primary marker 
of drug response in primary patient-derived 
tumors. As expected, RB-negative tumors 
routinely demonstrated robust expression of 
p16iNK4A; however, p16iNK4A expression was not 
always a surrogate marker for RB loss, sup-
porting the importance of direct screening 
of tumors for RB expression to select patients 
appropriate for CDK4/6 inhibitor clinical trials.
in the second study, McClendon et 
al. investigated the efficacy of PD0332991 
in combination with doxorubicin in triple-
negative breast cancer cell lines. Again, RB 
functionality was paramount in determining 
response to either PD0332991 monotherapy 
or combination treatment. in RB-deficient 
cancer cells, CDK4/6 inhibition had no effect 
in either instance. However, in RB-expressing 
cancer cells, CDK4/6 inhibition and doxorubi-
cin provided a cooperative cytostatic effect, 
although doxorubicin-induced cytotoxicity 
was substantially reduced, assessed by mark-
ers for mitotic catastrophe and apoptosis. 
Additionally, despite cytostatic cooperativity, 
CDK4/6 inhibition maintained the viability of 
RB-proficient cells in the presence of doxo-
rubicin, which repopulated the culture after 
removal of drug. These results reflect previous 
data demonstrating that ectopic expression of 
p16iNK4A can protect cells from the lethal effects 
of DNA damaging and anti-mitotic chemo-
therapies.7 Similar results have been reported 
in MMTV-c-neu mice bearing RB-proficient 
HeR2-driven tumors, where PD0332991 com-
promised carboplatin-induced regressions,8 
suggesting that DNA-damaging treatments 
should not be combined concomitantly with 
CDK4/6 inhibition in RB-proficient tumors.
To combine CDK4/6 inhibition with cyto-
toxics, sequential treatment may be consid-
ered, in which CDK4/6 inhibition is followed by 
DNA damaging chemotherapy; cells relieved 
of G1 arrest may synchronously enter S phase, 
where they may be most susceptible to agents 
disrupting DNA synthesis. Release of myeloma 
cells from a prolonged PD0332991-mediated 
G1 block leads to S phase synchronization; 
interestingly, all scheduled gene expression 
is not completely restored (including factors 
critical to myeloma survival such as iRF4), fur-
ther favoring apoptotic responses to cytotoxic 
agents.9 Furthermore, in RB-deficient tumors, 
CDK4/6 inhibitors may be used to maximize 
the therapeutic window between transformed 
and non-transformed cells treated with che-
motherapy. in contrast to RB-deficient can-
cer cells, RB-proficient non-transformed cells 
arrested in G1 in response to PD0332991 are 
afforded protection from DNA damaging 
agents, thereby reducing associated toxicities, 
including bone marrow suppression.8
in summary, the current work provides 
evidence for RB expression as a determinant 
of response to CDK4/6 inhibition in primary 
tumors and highlights the complexity of com-
bining agents targeting the cell cycle machin-
ery with DNA damaging treatments.
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eukaryotic cells ensure that DNA is replicated 
only once per cell cycle. The initiation of DNA 
replication is dependent on the formation of 
the pre-replicative complex (pre-RC) on rep-
lication origins. The six components of origin 
recognition complex (Orc1–6p) are bound to 
the origins, followed by Cdc6p, Cdt1p and the 
Mcm2–7p complex, to constitute pre-RC. The 
pre-RC is then activated by the Dbf kinase-
Cdc7p complex to initiate DNA replication, 
where the Mcm complex acts as a helicase.1 
After initiation, the pre-RC complex is disas-
sembled and/or inactivated in order to inhibit 
re-initiation until the next cell cycle. The inhibi-
tion of the pre-RC assembly can be achieved 
by protein degradation through ubiquitina-
tion, translocation and/or phosphorylation of 
the pre-RC components. Regulation of the Orc 
complex across species is diverse. in yeast, the 
Orc complex is probably associated on the 
origin throughout the cell cycle, and the Orc 
proteins are phosphorylated by cyclin/CDK 
complex to inhibit the function.2 in humans, 
Orc1 is ubiquitinated by SCFskp2 complex and 
degraded by the proteasome.3 Orc2 is asso-
ciated with heterochromatin, centromere 
and centrosome depending on the cell cycle 
stage.3,4
Previously Shen et al. showed that Orc-
associated protein (ORCA) utilizes WD40 
repeats to associate with DNA replication fac-
tors such as Orc, Cdt1 and Geminin in human 
cells. The WD40 repeats in ORCA are also 
required for chromatin binding, suggesting 
that ORCA may anchor other DNA replication 
factors to chromatin. ORCA stabilizes Orc to 
chromatin, indicating that ORCA positively 
regulates the initiation of DNA replication.5 
The siRNA treatment against Orc2 showed 
decreased amount of ORCA, suggesting 
that the stability of ORCA is dependent on 
Orc2.6 Therefore, the Orc2-ORCA binding 
facilitates the stability of this complex. it has 
been shown that ORCA protein levels are 
peaked at G1 phase. in a previous issue of Cell 
Cycle, Shen et al. investigated the molecular 
mechanism by which ORCA is regulated in a 
cell cycle-dependent manner.7 The authors 
showed that ORCA is polyubiquitinated at 
the WD40 repeat region, where it is recog-
nized by Orc2. They observed an elevated 
ORCA ubiquitination level at G1/S boundary 
that coincides with ORCA protein degrada-
tion. Furthermore, Orc2 is associated only with 
non-ubiquinated ORCA, indicating that Orc2 
prevents ORCA from ubiquitin-mediated deg-
radation. The authors proposed a model that 
Orc2 releases from chromatin after G1, which 
may trigger ORCA ubiquitination and degra-
dation (Fig.  1). Therefore, ORCA degradation 
prevents Orc2 loading on the chromatin after 
G1 to allow only one S-phase per cell cycle. 
This cell cycle-dependent ORCA regulation 
may allow Orc2 to obtain diverse functions 
as well as timely initiation of DNA replication 
on the specific origins. The novel mechanism 
to control Orc components through ORCA 
may be a key mechanism to control DNA 
re-replication.
References
1. Bell SP, et al. Annu Rev Biochem 2002; 71:333-
74; PMiD:12045100; http://dx.doi.org/10.1146/
annurev.biochem.71.110601.135425.
2. Nguyen VQ, et al. Nature 2001; 411:1068-
73; PMiD:11429609; http://dx.doi.
org/10.1038/35082600.
3. Méndez J, et al. Mol Cell 2002; 9:481-91; 
PMiD:11931757; http://dx.doi.org/10.1016/S1097-
2765(02)00467-7.
4. Prasanth SG, et al. eMBO J 2004; 23:2651-63; 
PMiD:15215892; http://dx.doi.org/10.1038/
sj.emboj.7600255.
5. Shen Z, et al. Mol Cell 2010; 40:99-111; 
PMiD:20932478; http://dx.doi.org/10.1016/j.mol-
cel.2010.09.021.
6. Shen Z, et al. Mol Cell Biol 2012; 32:3107-20; 
PMiD:22645314; http://dx.doi.org/10.1128/
MCB.00362-12.
7. Shen Z, et al. Cell Cycle 2012; 11; PMiD:22935713; 
http://dx.doi.org/10.4161/cc.21870.
ORCA is regulated by ubiquitin-mediated degradation to control Orc2 function  
Comment on: Shen Z, et al. Cell Cycle 2012; 11:3578–89;  
PMID:22935713; http://dx.doi.org/10.4161/cc.21870
Amy E. Ikui; Brooklyn College; Brooklyn, NY USA; Email: AIkui@brooklyn.cuny.edu; http://dx.doi.org/10.4161/cc.22391
Figure 1. A model: cell cycle-dependent control of ORCA determines Orc2 binding to origin.
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The oncogene Evi1, which codes for a 
sequence-specific transcription factor, was 
cloned as a target of activating retroviral inser-
tions in murine myeloid tumors 24 y ago.1 Soon 
thereafter, its human homolog was found to 
be transcriptionally activated through rear-
rangements of chromosome band 3q26,2,3 
which are associated with a poor progno-
sis in acute myeloid leukemia (AML).4 Since 
then, EVI1 has emerged repeatedly as retroviral 
integration site in different organisms, and a 
role of its overexpression as an indicator of 
poor prognosis in a variety of hematopoietic 
malignancies, as well as some solid tumors, 
has been firmly established. Because of its 
well-documented clinical importance, under-
standing the mechanism(s) of action of EVI1 
is of high significance. However, EVI1 reveals 
its secrets only slowly, with merely 475 articles 
containing the search terms “eVi1,” “eVi-1” or 
“MeCOM” (the officially assigned, but still rarely 
used, gene name) deposited in PubMed at the 
time of writing.
One of the most recent occasions on 
which EVI1 gained negative prominence was 
in the context of a human gene therapy trial 
for X-linked chronic granulomatous disease 
(X-CGD).5 Transplantation of gene-modified, 
autologous hematopoietic stem cells initially 
provided substantial clinical benefit to two 
young adults with X-CGD. However, over 
time, hematopoiesis became dominated by 
clones with vector integrations into, and tran-
scriptional activation of, the EVI1 locus. These 
clones finally evolved into myeloid malignan-
cies, acquiring monosomy 7, a chromosome 
aberration frequently associated with EVI1 
overexpression in AML, during this process. 
As a preliminary mechanistic explanation for 
these findings, experimental expression of 
EVI1 in human diploid fibroblasts increased 
the numbers of cells with aberrant centrosome 
numbers.5
in the September 15th issue of Cell Cycle, 
Karakaya and colleagues confirmed and 
extended these observations.6 Using U2OS 
osteosarcoma cells inducibly expressing EVI1 
as a model, they show that only 72 h after 
induction of EVI1, 17% of the cells contained 
centrosome amplifications vs. 5% of the con-
trol cells. Analysis of nuclear morphology and 
time-lapse video microscopy suggested that 
supernumerary centrosomes resulted from a 
cytokinesis defect that is known to activate 
a p53-dependent tetraploidy checkpoint. 
indeed, induction of EVI1 upregulated p53 
and siRNA-mediated p53 depletion increased 
the percentage of polyploid cells after EVI1 
induction. Furthermore, the vast majority of 
EVI1-overexpressing cells with centrosome 
amplification had low or undetectable levels 
of the proliferation marker Ki67, indicating 
that EVI1-induced centrosome aberrations 
were largely confined to cells in G0 or early G1, 
and confirming that EVI1-induced tetraploidi-
zation caused a cell cycle arrest.6
These data, together with those from the 
X-CGD study,5 establish genomic instability as 
a not previously reported consequence of EVI1 
overexpression, which also might explain its fre-
quent association with monosomy 7. it should 
be pointed out, though, that chromosome 
aberrations can also emerge through selection 
on the background of normal missegregation 
rates rather than through increased genetic 
instability.7 in fact, in the Mitelman database,8 
in ~39% of AML cases with a 3q26 aberration 
this was the sole cytogenetic anomaly, and for 
~82% of 3q26 rearranged cases, only a single 
clone was reported [compared with ~43% 
and ~83%, respectively, for the prognosti-
cally favorable t(8;21)(q22;q22)]. These data 
do not argue for greatly increased rates of 
chromosome instability as a consequence of 
EVI1 overexpression. However, excessive insta-
bility would likely pose the danger of lethal 
genetic aberrations and thus not be beneficial 
to a tumor cell, while low-level instability may 
become apparent from cytogenetic data only 
through more detailed analyses. in addition 
to eventual subtle effects on karyotype at 
the time of diagnosis, modest EVI1-induced 
chromosome instability raises the intriguing 
possibility that EVI1 overexpression may cause 
poor prognosis at least in part by facilitating 
acquisition of aberrations that allow tumor 
cells to escape chemotherapy-induced apop-
tosis. This hypothesis can be tested through 
quantitative evaluation of chromosome aber-
rations and clones at diagnosis and relapse 
(which is caused by cells that survived the 
initial therapy) in patients with 3q26 rear-
ranged/EVI1 overexpressing AML and suitable 
controls. The work of Karakaya et al., in addi-
tion to the novel information it provides as 
it stands, therefore opens new perspectives 
that may lead to substantial advances in our 
understanding of how overexpression of EVI1 
contributes to poor prognosis in AML and 
other malignancies.
References
1. Morishita K, et al. Cell 1988; 54:831-40; 
PMiD:2842066; http://dx.doi.org/10.1016/S0092-
8674(88)91175-0.
2. Morishita K, et al. Proc Natl Acad Sci USA 1992; 
89:3937-41; PMiD:1570317; http://dx.doi.
org/10.1073/pnas.89.9.3937.
3. Fichelson S, et al. Leukemia 1992; 6:93-9; 
PMiD:1552747.
4. Lugthart S, et al. J Clin Oncol 2010; 28:3890-8; 
PMiD:20660833; http://dx.doi.org/10.1200/
JCO.2010.29.2771.
5. Stein S, et al. Nat Med 2010; 16:198-204; 
PMiD:20098431; http://dx.doi.org/10.1038/
nm.2088.
6. Karakaya K, et al. Cell Cycle 2012; 11:3492-503; 
PMiD:22894935; http://dx.doi.org/10.4161/
cc.21801.
7. Lengauer C, et al. Nature 1998; 396:643-9; 
PMiD:9872311; http://dx.doi.org/10.1038/25292.
8. Mitelman F, et al. (2012) http://cgapncinihgov/
Chromosomes/Mitelman.
New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing 
aggressive malignant disease
Comment on: Karakaya K, et al. Cell Cycle 2012; 11:3492–503;  
PMID:22894935; http://dx.doi.org/10.4161/cc.21801
Rotraud Wieser; Department of Medicine I and Comprehensive Cancer Center; Medical University of Vienna; Vienna, Austria;  
Email: rotraud.wieser@meduniwien.ac.at; http://dx.doi.org/10.4161/cc.22392
www.landesbioscience.com Cell Cycle 3916
Addicted to PAR? A closer look at PARP inhibitor sensitivity
Comment on: Oplustilova L, et al. Cell Cycle 2012; 11:3837–50;  
PMID:22983061; http://dx.doi.org/10.4161/cc.22026 
Matthias Altmeyer; Chromosome Stability and Dynamics Unit; Department of Disease Biology; Novo Nordisk Foundation Center for Protein Research;  
University of Copenhagen; Copenhagen, Denmark; Email: matthias.altmeyer@cpr.ku.dk; http://dx.doi.org/10.4161/cc.22393
Defects in genome maintenance and repair 
pathways are common features of human can-
cers. in some cases, specific DNA repair defects 
can render cancer cells dependent on back-up 
pathways for their survival, and targeting these 
back-up mechanisms is a promising strategy 
for cancer therapy.1 One example for such syn-
thetic lethality is the pronounced sensitivity of 
BRCA-deficient cancer cells, defective in DNA 
repair by homologous recombination (HR), 
to inhibition of poly(ADP-ribose) polymerases 
(PARPs).2 Consequently, PARP inhibitors have 
entered clinical trials as single agents, but 
also in combination therapy as chemo- or 
radiation-sensitizing drugs.3 Following excit-
ing proof-of-concept results, however, PARP 
inhibitors recently encountered first difficul-
ties, and the current challenge is to under-
stand why certain cancers respond better to 
these compounds than others.
in a study now published in Cell Cycle, 
Oplustilova and colleagues used a panel of 
human cancer cell lines derived from carcino-
mas of breast, prostate, colon, pancreas and 
ovary to study the response to PARP inhibition 
and analyze cellular determinants of sensitivity 
or resistance.4
Acquired resistance by drug efflux can 
be a major barrier to therapeutic efficacy, 
and Oplustilova et al. demonstrate that 
P-glycoprotein drug efflux pumps contribute 
to inhibitor resistance in colon cancer cells, 
thereby extending previous findings obtained 
in a mouse model for BRCA1-associated 
breast cancer.5 importantly, inhibition of 
P-glycoprotein by verapamil resulted in ele-
vated intracellular levels of the PARP inhibitor 
KU 58948 and restored inhibitor sensitivity, 
consolidating the notion that acquired resis-
tance by enhanced drug efflux can, in prin-
ciple, be overcome.
The authors also investigated a second 
mechanism of alleviated PARP inhibitor 
sensitivity based on the recent discovery that 
loss of the genome caretaker 53BP1 restores 
HR in BRCA1-deleted cells.6,7 Consistent with 
the proposed function of 53BP1 to restrict DNA 
end resection, exacerbate HR deficiency and 
enhance PARP inhibitor sensitivity, Oplustilova 
et al. show that shRNA-mediated depletion of 
53BP1 in a human BRCA1-defective breast can-
cer cell line reduced sensitivity to PARP inhibi-
tion. Given the aberrant reduction of 53BP1 
in subsets of BRCA-associated breast carcino-
mas and sporadic triple-negative breast can-
cers,7 immunohistochemical analyses of 53BP1 
expression, as also performed in the present 
study, might thus have predictive value when 
assessing PARP inhibitor sensitivity.
intrigued by the emerging notion that the 
concept of synthetic lethality could have wider 
applicability to other defects in the DNA dam-
age response network, and in line with pre-
vious studies demonstrating PARP inhibitor 
sensitivity associated with BRCA-independent 
HR defects,8 Oplustilova et al. show that even 
partial depletion of the MRN components 
MRe11 or NBS1 sensitizes to PARP inhibition, 
whereas ectopic expression in mutant cells 
had the opposite effect.
Further, arguing that ongoing PARP activ-
ity must be a prerequisite for PARP inhibitors 
to work, Oplustilova et al. went on to assess 
steady-state poly(ADP-ribose) (PAR) levels in 
different cell lines and report a correlation 
between detection of PAR and inhibitor sen-
sitivity. While these results generally support 
PAR levels as potential candidate biomarker, 
additional studies are needed to determine 
whether PAR detection is technically feasible 
in tissue biopsies, and whether PARP inhibi-
tor sensitivity is inevitably associated with 
detectable amounts of PAR, especially in light 
of the limited sensitivity of the available anti-
bodies for shorter PAR chains. Likewise, when 
Oplustilova et al. assessed RAD51 foci numbers 
as a surrogate marker for HR, several cell lines 
were sensitive to PARP inhibition, yet they 
had normal RAD51 foci levels, suggesting that 
either specific HR defects do not entail reduced 
RAD51 loading, or that synthetic lethality can 
be achieved through HR-independent mecha-
nisms. Together, these results raise the concern 
that use of single biomarkers could indeed be 
misleading, and that a combination of markers 
to assess which cancer cells are likely “addicted 
to PAR” might be more reliable. The study by 
Oplustilova et al. evaluates several of such can-
didate biomarkers and thus contributes to the 
collective effort to guide targeted cancer ther-
apy to those patients who might benefit most 
from PARP inhibitor treatment. However, it also 
illustrates once again that such guidance cru-
cially relies on a more detailed understanding 
of the complex DNA damage repair network 
and how the interacting pathways may be 
rewired in cancers with unstable genomes, 
as well as on deeper insights into the diverse 
functions of PARPs and how they contribute to 
synthetic lethality.
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it is easy to conceive that in a toxic environ-
ment most cells would abandon the division 
process. in the past decades, it has indeed 
become clear that cells have developed com-
plex cell cycle checkpoint mechanisms, which 
slow-down or stop cells from proliferating 
under challenging conditions. More recently, 
however, is the discovery and molecular char-
acterization of signaling cascades capable of 
integrating classical stress-activated responses 
and cell cycle checkpoints. A report published 
in a recent issue of Cell Cycle1 sheds light on the 
increasing complexity of such pathways. The 
authors found that the stress-activated pro-
tein kinases p38 and JNK cooperate with Chk1 
to block progression into mitosis under con-
ditions that alter DNA replication (i.e.,  treat-
ments of cells with antiproliferative drugs such 
as hydroxyurea, aphidicolin, camptothecin or 
etoposide). By using a combination of phar-
macological and genetic tools, together with 
precise protocols of cell cycle synchronization, 
the study shows compelling evidence that 
in murine NiH3T3 and embryonic fibroblasts, 
hydroxyurea (used at concentrations capable 
of abrogating DNA synthesis) added during 
progression through S-phase first induces an 
early acute activation of Chk1 that is immedi-
ately followed by a phasic activation of both 
p38 and JNK. Remarkably, p38 and JNK activi-
ties are triggered completely independent of 
ATM-ATR and Chk1 activation, since their activ-
ities were similarly induced in the presence of 
caffeine and UCN-01, respectively.
Additionally, activation of p38 under DNA 
replication blockade seems to be mediated by 
MKK3 and MKK6 (usual kinases turning-on p38 
signaling), while interestingly, JNK activation 
seems to be exclusively caused by MKK4 (one of 
the regular kinases switching-on the JNK path-
way) but not MKK7. Furthermore, downstream 
of p38 signaling, the authors unveiled activa-
tion of MK2 and MK3, kinases classically acti-
vated by p38 under many stressors. Strikingly, 
activation of MKK3/6-p38-MK2/3 and MKK4-
JNK cascades in the presence of hydroxyurea 
is required to suppress entry into mitosis as 
measured by reduced (Serine 10)-histone H3 
phospho-signal and impaired (Threonine 14 
and Tyrosine 15)-CDK1 dephosphorylation and 
activation. The effect on CDK1 activity is likely 
mediated by inhibitory regulation of members 
of the Cdc25 family of phosphatases (Fig. 1), 
as previously reported by others.2-4 Finally, the 
authors establish that at least p38α and p38β 
are involved in this mechanism; however, it is 
still unclear whether JNK1 and JNK2 both play 
significant roles in the process. Also, it remains 
to be identified which kinase(s) is (are) respon-
sible for the activation of the respective p38 
and JNK MKKs, under conditions blocking DNA 
synthesis/replication.
On the other hand, some progress has 
been made in the identification of substrates 
of the stress-activated protein kinases p38 
and JNK implicated in DNA replication. Two 
recent studies found that Cdt1 is phosphory-
lated, probably at several residues, by both 
p38 and JNK, in the presence of genotoxic5 
(UV-C) and non-genotoxic6 (including sorbitol 
and anisomycin) stressors. Cdt1 is a key DNA 
replication licensing factor that contributes 
with Cdc6 to ensure proper loading of the 
MCM complex onto chromatin to form the pre-
replication complex. Notably, stress-mediated 
phosphorylation of Cdt1 blocks its degrada-
tion during S-phase,5,6 leads to the dissocia-
tion of the histone acetylase HBO1/KAT7 from 
replication origins6 and compromises the abil-
ity of Cdt1 to instigate loading of the MCM 
complex,5 therefore blocking initiation of DNA 
replication.5,6
Moreover, JNK was also found to phos-
phorylate the RiNG-finger type e3 ubiquitin 
ligase Rad18, involved in postreplication repair 
of damaged DNA (UV-C irradiation). JNK-
mediated Rad18 phosphorylation appears to 
facilitate recruitment of the translesion synthe-
sis DNA polymerase Polη to stalled replication 
forks.7 Polη is then presumably capable of 
DNA synthesis over the damaged DNA, later 
allowing DNA replication by conventional DNA 
Figure 1. A proposed model of signaling circuitry integrating stress-response and cell cycle 
checkpoint pathways. Refer to text and references for details.
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polymerases to occur. This intriguing observa-
tion rather suggests a role for JNK in DNA dam-
age response tolerance pathways.
Based on those and other studies describ-
ing a direct control of cell cycle regulators by 
stress-response pathways, at least in the case 
of JNK, it is possible to advocate a general 
function in cellular genome integrity mainte-
nance, through the regulation of substrates 
such as Cdt1 and Rad18, or histone H3 and 
Cdh1/FZR1, under toxic5-7 or unperturbed8,9 
conditions, respectively. Finally, according 
to our current understanding of the stress-
activated signaling pathways, it is notewor-
thy that the analytical dynamics, subcellular 
localization and temporal occurrence of the 
stress input (directly associated with cell cycle 
checkpoints or not) would likely determine 
not only the strength, duration and diffusion 
of the stress response but more importantly 
its final functional outcome.1 in practical terms, 
the modulability of the stress-response could 
decide which exact pathways are activated 
and which substrates need to be accordingly 
modified. Given the growing involvement of 
stress responses in the control of cell cycle 
(checkpoint) mechanisms, we would speculate 
that in coming years, the cell cycle-related 
phosphoproteome governed by canonical 
stress kinases will continue to augment.
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